Bristol-Myers Squibb (NYSE:BMY) Shares Acquired by National Bank of Canada FI

National Bank of Canada FI boosted its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 88.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,827,499 shares of the biopharmaceutical company's stock after purchasing an additional 1,326,387 shares during the period. National Bank of Canada FI owned about 0.14% of Bristol-Myers Squibb worth $149,176,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BMY. Legacy Financial Group LLC purchased a new position in Bristol-Myers Squibb during the third quarter valued at $39,000. Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of Bristol-Myers Squibb by 143.2% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 3,308 shares of the biopharmaceutical company's stock valued at $192,000 after acquiring an additional 1,948 shares during the period. Northstar Asset Management LLC raised its stake in Bristol-Myers Squibb by 18.4% during the 3rd quarter. Northstar Asset Management LLC now owns 5,148 shares of the biopharmaceutical company's stock worth $299,000 after acquiring an additional 800 shares during the period. Beacon Financial Advisory LLC increased its stake in shares of Bristol-Myers Squibb by 3.2% in the third quarter. Beacon Financial Advisory LLC now owns 13,555 shares of the biopharmaceutical company's stock worth $787,000 after purchasing an additional 426 shares in the last quarter. Finally, Canal Capital Management LLC lifted its stake in shares of Bristol-Myers Squibb by 2.9% during the 3rd quarter. Canal Capital Management LLC now owns 79,381 shares of the biopharmaceutical company's stock valued at $4,607,000 after buying an additional 2,225 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BMY. Wells Fargo & Company boosted their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an "equal weight" rating in a research report on Thursday, April 18th. StockNews.com downgraded Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Monday, April 15th. Barclays reduced their price objective on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an "equal weight" rating on the stock in a research report on Friday, April 26th. Redburn Atlantic lowered shares of Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $77.00 to $54.00 in a research report on Tuesday, February 6th. Finally, Societe Generale cut shares of Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a research note on Monday, March 11th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Bristol-Myers Squibb currently has an average rating of "Hold" and an average target price of $60.00.

Bristol-Myers Squibb Trading Up 0.7 %

BMY stock traded up $0.29 during mid-day trading on Friday, reaching $43.99. 12,104,489 shares of the stock traded hands, compared to its average volume of 14,314,010. Bristol-Myers Squibb has a one year low of $43.33 and a one year high of $69.10. The stock has a market capitalization of $89.17 billion, a PE ratio of -14.19, a PEG ratio of 14.72 and a beta of 0.45. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The business has a 50-day moving average price of $50.37 and a two-hundred day moving average price of $50.74.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. During the same period in the prior year, the firm posted $2.05 EPS. The firm's revenue was up 4.7% compared to the same quarter last year. Equities research analysts expect that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 5.46%. The ex-dividend date of this dividend was Thursday, April 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.